

## People



### Jack Elands joins IDBS

Jack Elands, Head of Marketing and Sales at BioSignal Packard, has recently been appointed Vice-President of Marketing at IDBS

(Guildford, UK). Prior to working at BioSignal Packard, Elands was manager of all Zymark Corporation's products in the drug discovery sector and previously established the screening operation at Marion Merrell Dow.

Chairman and CEO of IDBS, Neil Kipling, said: 'Jack will be a key player in the delivery of IDBS' vision of providing a common, integrated software framework for scientific discovery. As a well-known and respected figure in the biopharmaceutical industry, Jack has a valuable set of talents and experience.'

### Cancer research pioneer honoured

Alan Sartorelli, the pioneer in cancer pharmacology, was awarded the American Association of Cancer Research (AACR) 14th Bruce F. Cain Memorial Award at the association's 92nd annual meeting in New Orleans (LA, USA) this year. The award was given in recognition of the outstanding preclinical research that he and his team have conducted in the search for cancer treatments.

Sartorelli is known for his work on evaluating the role of tumour cell hypoxia in anticancer drug action and for his seminal work on differentiation induced by therapeutic agents. His group also designed, synthesized and evaluated several novel anticancer agents such as the ribonucleotide reductase inhibitor, Triapine, and the sulfonyl hydrazine prodrug candidate, VNP40101M, both licensed by Yale University to Vion Pharmaceuticals (New Haven, CT, USA).

Sartorelli is one of the founding members of Vion Pharmaceuticals and is Chairman of its Scientific Advisory Board. He is also The Alfred Gilman Professor of Pharmacology at Yale School of Medicine (Yale University, New Haven, CT, USA). The

Bruce F. Cain Memorial Award was established by Warner-Lambert to honour the memory of Bruce F. Cain from New Zealand for his work in the design, synthesis and biological evaluation of potential anticancer drugs.



### Paul Clewlow joins Pharmaceutical Profiles

Pharmaceutical Profiles (Nottingham, UK) has appointed Paul Clewlow as their new Business

Development Director. This role will give Clewlow overall responsibility for the company's sales growth and management of their commercial business relationships in Europe, the USA and Japan. He will also be responsible for identifying new clients for the company and for overseeing the company's marketing and promotional campaigns.

Clewlow joins the company from Medeval (Manchester, UK) where he was Head of Business Development. He has more than 12 years' experience in international sales, marketing and business development, as well as experience in the oil and fine chemical industries gained from companies such as Exxon and Ultrafine Chemicals.

### New VP of Business Development at Biostratum

Gary M. Gordon has been appointed to the position of Vice-President of Business Development at Biostratum (Research Triangle Park, NC, USA). Gordon has previously held several senior management positions. These include being Director of Finance, Administration and Business Development and Chief Financial Officer at Sentinel Biosciences (Palo Alto, CA, USA), a company that he co-founded. His duties at Sentinel included raising start-up capital, research funding and establishing research collaborations, and served as secretary and member of the Board. Previous to that position, he was Director of Corporate Development at Genelabs Technologies

(Redwood City, CA, USA) and worked in the International Pharmaceutical Marketing division of Warner-Lambert.

### Paul Goddard joins Alchemia as Chairman

Paul Goddard has joined Alchemia (Brisbane, Australia) as Chairman, after being President and CEO of Elan Pharmaceuticals, a division of Elan Corporation. He joined Elan Pharmaceuticals in 1998 as a result of its acquisition of Neurex Corporation where he had been Chairman and CEO. Prior to working at Neurex, Goddard held several senior management positions at SmithKline Beecham Pharmaceuticals over a 15-year period.

At Neurex, Goddard raised over US\$100 million in financing before it was sold to Elan Corporation for US\$750 million. He also unified four acquired companies at Elan Corporation and evolved Elan Pharmaceuticals into the largest division in the corporation.

Travis Ramsdale, CEO of Alchemia said, 'Alchemia will greatly benefit from the extensive pharmaceutical and biotechnology industry experience of Dr Goddard. The company would like to express its gratitude to Mr Bill Stubbs, our previous Chairman, for his valuable contributions in the early stages of Alchemia's development.'

### Two new product managers at Zymark

Zymark Corporation (Hopkinton, MA, USA) has recently announced the appointment of Stephanie Wilson and Jeffrey Donahue to the positions of Project Manager for Prelude™ Sample Processing Workstations and for Liquid Handling Products, respectively.

Wilson brings to the job experience in product management, worldwide sales and marketing, and marketing leadership. Wilson was previously Manager of Technical Development at Elan Diagnostics, a division of Elan Pharmaceuticals. Prior to this, she has held product management positions at Boston Biomedica and Bayer Corporation.

Meanwhile, Donahue brings tactical and strategic planning, development, technology transfer, project management and technical support service skills. Donahue was previously Manager of Technical Support and Service in the Drug Discovery Business Group at Bayer Corporation.